Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Paroxetine - Novo Nordisk

Drug Profile

Paroxetine - Novo Nordisk

Alternative Names: Aropax; BRL 29060; BRL 29060A; Deroxat; Divarius; FG 7051; Frosinor; Motivan; NNC 207051; Paxil; Paxil CR; Seroxat; SI 211103; Tagonis

Latest Information Update: 31 Aug 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novo Nordisk
  • Developer GlaxoSmithKline; GlaxoSmithKline KK; Novo Nordisk; Scios; Vectura
  • Class Antidepressants; Anxiolytics; Benzodioxoles; Fluorobenzenes; Irritable bowel syndrome therapies; Piperidines; Small molecules
  • Mechanism of Action Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Depressive disorders; Generalised anxiety disorder; Major depressive disorder; Obsessive-compulsive disorders; Panic disorder; Post-traumatic stress disorders; Premenstrual dysphoric disorder; Social phobia
  • Phase I Anxiety disorders

Most Recent Events

  • 26 Jul 2018 GlaxoSmithKline completes a phase I trial in Anxiety disorders (In volunteers) in China (PO) (NCT03329573)
  • 30 May 2018 Phase-I clinical trials in Anxiety disorders (In volunteers) in China (PO) (NCT03329573)
  • 06 Nov 2017 GlaxoSmithKline plans a phase I trial for Anxiety disorders (In volunteers) in June 2018 (PO) (NCT03329573)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top